MY205443A - Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Info

Publication number
MY205443A
MY205443A MYPI2020001882A MYPI2020001882A MY205443A MY 205443 A MY205443 A MY 205443A MY PI2020001882 A MYPI2020001882 A MY PI2020001882A MY PI2020001882 A MYPI2020001882 A MY PI2020001882A MY 205443 A MY205443 A MY 205443A
Authority
MY
Malaysia
Prior art keywords
diseases
treatment
pharmaceutical compositions
novel compounds
inflammatory disorders
Prior art date
Application number
MYPI2020001882A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
David Amantini
Ren Alexandre Galien
Ramos Miriam Lpez
Denis Maurice Annoot
Ghjuvanni Petru Diunisu Coti
Pieter Isabelle Roger Claes
Sbastien Laurent Xavier Martina
Oscar Mammoliti
Der Plas Steven Emiel Van
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MY205443A publication Critical patent/MY205443A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI2020001882A 2017-10-20 2018-10-11 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders MY205443A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Publications (1)

Publication Number Publication Date
MY205443A true MY205443A (en) 2024-10-22

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001882A MY205443A (en) 2017-10-20 2018-10-11 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (30)

Country Link
US (2) US11564923B2 (https=)
EP (2) EP3697784B9 (https=)
JP (2) JP7292271B2 (https=)
KR (1) KR102757425B1 (https=)
CN (2) CN111225916B (https=)
AR (1) AR113784A1 (https=)
AU (2) AU2018350592B2 (https=)
CA (1) CA3079449A1 (https=)
CO (1) CO2020005200A2 (https=)
DK (1) DK3697784T5 (https=)
ES (1) ES2967432T3 (https=)
FI (1) FI3697784T5 (https=)
GB (1) GB201717260D0 (https=)
HR (1) HRP20231315T1 (https=)
HU (1) HUE063998T2 (https=)
IL (2) IL302615B2 (https=)
LT (1) LT3697784T (https=)
MA (1) MA50391B1 (https=)
MX (1) MX2020003863A (https=)
MY (1) MY205443A (https=)
PH (1) PH12020550230A1 (https=)
PL (1) PL3697784T3 (https=)
PT (1) PT3697784T (https=)
RS (1) RS64800B1 (https=)
SG (1) SG11202003516TA (https=)
SI (1) SI3697784T1 (https=)
SM (1) SMT202300377T1 (https=)
TW (2) TWI866258B (https=)
WO (1) WO2019076716A1 (https=)
ZA (1) ZA202002166B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
AU2020284742B2 (en) * 2019-05-28 2026-03-05 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022310901A1 (en) 2021-07-12 2024-02-22 Galapagos Nv Treatment of inflammatory diseases
AU2022412835A1 (en) 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161327A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP2024082106A (ja) * 2022-12-07 2024-06-19 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
CR20250317A (es) 2023-01-18 2025-08-29 Galapagos Nv Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios
AU2024209905A1 (en) 2023-01-19 2025-09-04 Galapagos Nv Imidazo[4,5-b]pyridine derivatives useful for the treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases and proliferative diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
ES2967432T3 (es) 2024-04-30
BR112020007541A2 (pt) 2020-09-24
FI3697784T5 (fi) 2024-01-12
RS64800B1 (sr) 2023-11-30
SMT202300377T1 (it) 2024-01-10
CN111225916B (zh) 2023-11-03
IL302615B2 (en) 2024-10-01
AU2018350592A1 (en) 2020-06-04
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
FI3697784T3 (fi) 2023-10-31
AU2023201522B2 (en) 2024-11-28
IL302615B1 (en) 2024-06-01
EP3697784A1 (en) 2020-08-26
TW201918483A (zh) 2019-05-16
SI3697784T1 (sl) 2023-11-30
EP3697784B1 (en) 2023-10-04
HUE063998T2 (hu) 2024-02-28
RU2020116376A (ru) 2021-11-22
EP4265254A2 (en) 2023-10-25
GB201717260D0 (en) 2017-12-06
JP2020537672A (ja) 2020-12-24
HRP20231315T1 (hr) 2024-02-16
CN117534670A (zh) 2024-02-09
CA3079449A1 (en) 2019-04-25
JP7654031B2 (ja) 2025-03-31
AR113784A1 (es) 2020-06-10
AU2018350592B2 (en) 2022-12-22
TWI805629B (zh) 2023-06-21
CO2020005200A2 (es) 2020-05-29
ZA202002166B (en) 2021-05-26
PT3697784T (pt) 2024-01-09
US20230310433A1 (en) 2023-10-05
IL273943A (en) 2020-05-31
PL3697784T3 (pl) 2024-03-11
LT3697784T (lt) 2023-10-25
WO2019076716A1 (en) 2019-04-25
JP7292271B2 (ja) 2023-06-16
TW202411229A (zh) 2024-03-16
CN111225916A (zh) 2020-06-02
US12472181B2 (en) 2025-11-18
TWI866258B (zh) 2024-12-11
US11564923B2 (en) 2023-01-31
SG11202003516TA (en) 2020-05-28
DK3697784T3 (da) 2023-10-30
RU2020116376A3 (https=) 2021-11-22
KR20200074178A (ko) 2020-06-24
IL302615A (en) 2023-07-01
DK3697784T5 (da) 2024-01-15
KR102757425B1 (ko) 2025-01-20
US20210169879A1 (en) 2021-06-10
MA50391A (fr) 2021-04-21
IL273943B2 (en) 2023-10-01
MX2020003863A (es) 2020-08-13
JP2023113834A (ja) 2023-08-16
PH12020550230A1 (en) 2021-02-08
AU2023201522A1 (en) 2023-04-13
EP4265254A3 (en) 2024-03-13
MA50391B1 (fr) 2023-11-30

Similar Documents

Publication Publication Date Title
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MY201849A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of disease
PH12020552160A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2021013803A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12014502615A1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12019502853A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2016172134A3 (en) Novel compounds
TW201613601A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12021552377A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2018010218A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de fibrosis.
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12021552376A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
NZ803938A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
NZ803938B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.